ADA 2019 – a good start for Beta Bionics
The iLet system showed decent blood sugar control in its first trial, but the highly automated system is far from proven.
ADA 2019 – Provention claims success where Lilly failed
The company’s teplizumab delays development of type 1 diabetes, but Lilly’s failure with the same project nine years earlier casts a long shadow.
ADA 2019 – Rewind makes Lilly’s Trulicity look average
Less than emphatic cardiovascular outcomes data leave Lilly looking vulnerable to Novo Nordisk’s competing drugs.
VTV’s diabetes reinvention gains some ground
After crashing on a late-stage Alzheimer’s failure last year VTV Therapeutics has taken a small step forward in type 1 diabetes.
Rose-tinted glasses might not save Genkyotex
Genkyotex has dredged the data to find a glimmer of hope with GKT831 in primary biliary cholangitis, but cash is running short.
Boehringer pushes pipeline progress
The notoriously secretive German pharma company Boehringer Ingelheim has made much of a new drive towards transparency, but there are still things it would rather keep to…
ISN 2019 – Kidney benefit could help Invokana compete again
Johnson & Johnson’s Invokana has fallen behind SGLT2 rivals over amputation fears, but success in the Credence renal trial, profiled at the International Society of…
Poxel tastes sweet success at last
The group follows licensing deals with Dainippon and Roivant with a pivotal study win.
Upcoming events – Novo takes aim at type 1 diabetes and Aslan wants to roar
Novo Nordisk hopes that its attempt to preserve beta cells will fare better than Caladrius’s, while Aslan tries its hand at DHODH inhibition.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.